Clinical Trial

Immunogenicity of Fractional Dose of the HPV Vaccines

Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This randomized phase IV trial compares intramuscular and intradermal fractional dose of bivalent HPV vaccine to fractional dose of nonavalent HPV vaccine among men and women aged 27-45 years in Seattle, Washington. Participants will have immune response assessed at baseline, 4 weeks, 6 months, and 12 months
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-03-17; most recent amendment 2026-04-28.
Status change: Not Yet Recruiting → Active, Not Recruiting 2023-02-13
Trial Details
NCT Number NCT05291871
Lead Sponsor University of Washington
Conditions HPV Infection, HPV Vaccine
Enrollment 92 participants
Start Date 2022-06-15
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-05